Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The End Is Nigh For Mylan, But How Different Will The New Company Be?

Executive Summary

Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.

You may also be interested in...



Divided FTC Okays Mylan-Upjohn Merger But Election Outcome Could Impede Future Deals

Commissioners vote 3-2 that Mylan and Pfizer’s Upjohn can combine after divesting seven products; dissenting votes focus on price fixing allegations as commissioners Chopra and Slaughter criticize majority for not addressing government’s case against Pfizer and Mylan. Former FTC attorneys note that if Biden wins the presidential election, he could nominate one of the dissenters to FTC chair and give more traction to their views.

Mylan Will Invest $1bn In India

Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.

Will The Pfizer-Mylan Deal Face Antitrust Hurdles?

It's possible the US Federal Trade Commission could require Mylan or Pfizer's Upjohn to divest some pharmaceuticals as the companies have more than 70 overlapping products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel